IP Library › Granted Patent US 6,943,240
Granted Patent B2
US 6,943,240 · App. 09/954,987 · Granted Sep 13, 2005

Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist

Assignee: Coley Pharmaceuticals GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,943,240
App. No.
09/954,987
Granted
Sep 13, 2005
Kind
B2
Abstract

The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8. Methods are included for screening for ligands of TLR7 and TLR8, as well as for inhibitors and agonists and antagonists of signaling mediated by TLR7 and TLR8.

Claims (9)

1. An isolated nucleic acid molecule which encodes a Toll-like receptor 9 (TLR9) polypeptide HTLR9-CXXCm, said polypeptide comprising an amino acid sequence of SEQ ID NO:6 except for substitution of amino acids 269-274 of SEQ ID NO:6 with amino acids 269-274 of SEQ ID NO:3.

2. An expression vector comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter.

3. A host cell comprising the expression vector of claim 2 .

4. The host cell of claim 3 , further comprising at least one expression vector selected from the group consisting of:

(a) an expression vector comprising a nucleic acid molecule which encodes an isolated TLR7 polypeptide operably linked to a promoter, and

(b) an expression vector comprising a nucleic acid molecule which encodes an isolated TLR8 polypeptide operably linked to a promoter.

5. The host cell of claim 3 , further comprising a reporter gene construct comprising a reporter gene operatively linked to a promoter sensitive to NF-κB.

6. The host cell of claim 3 , wherein the host cell is a 293 fibroblast cell.

7. The host cell of claim 5 , wherein the host cell is a 293 fibroblast cell.

Assignments (2)
CONFIRMATION OF EXCLUSIVE PATENT LICENSE Recorded Dec 20, 2005
From: COLEY PHARMACEUTICAL GROUP, INC.; COLEY PHARMACEUTICAL GROUP, LTD.; COLEY PHARMACEUTICAL, GMBH
To: PFIZER INC.
Reel/Frame 017353/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2002
From: BAUER, STEFAN; LIPFORD, GRAYSON; WAGNER, HERMANN
To: COLEY PHARMACEUTICAL GMBH
Reel/Frame 012601/0595 →
Continuity (5)
Provisional Application 6030021000 · Jun 22, 2001
Provisional Application 6029172600 · May 17, 2001
Provisional Application 6026365700 · Jan 23, 2001
Provisional Application 6023303500 · Sep 15, 2000
Related Publication 20030104523A1 · Jun 5, 2003